Business Context and Reporting Period
Company: InspireMD, Inc. (NSPR)
Filing Type: Form 8-K (Current Report)
Date of Report: July 9, 2025
Event: Regulation FD Disclosure regarding the U.S. commercial launch of the CGuard® Prime Carotid Stent System.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change disclosed is the commencement of commercial sales in the United States for the CGuard® Prime Carotid Stent System, a device designed for the prevention of stroke.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release announcing the commercial launch of the CGuard® Prime system. No specific financial guidance or quantitative outlook is provided in this document.
Risks and Contingencies: The filing notes that the information furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, limiting its incorporation by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific details on the CGuard® Prime launch strategy and market expectations.
- Review subsequent quarterly reports (10-Q) or annual reports (10-K) for the financial impact of this commercial launch.
- Confirm the regulatory status and FDA clearance details of the CGuard® Prime Carotid Stent System.
- Monitor future 8-K filings for any updates on sales performance or additional regulatory milestones.